Temozolomide and cisplatin in relapsed/refractory acute leukemia

Temozolomide and cisplatin in relapsed/refractory acute leukemia

<p>Abstract</p> <p>Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fifteen patients had AML, 3 had ALL, and 2 had biphenotypi...

Full description

Bibliographic Details
Main Authors: Rasul Muhammad, Ponce Doris, Katragadda Sreedhar, Seiter Karen, Ahmed Nasir
Format: Article
Language:English
Published: BMC 2009-05-01
Series:Journal of Hematology & Oncology
Online Access:http://www.jhoonline.org/content/2/1/21
id doaj-d95f133a22c148348c37a9c7a8babb30
record_format Article
spelling doaj-d95f133a22c148348c37a9c7a8babb302020-11-24T21:07:47ZengBMCJournal of Hematology & Oncology1756-87222009-05-01212110.1186/1756-8722-2-21Temozolomide and cisplatin in relapsed/refractory acute leukemiaRasul MuhammadPonce DorisKatragadda SreedharSeiter KarenAhmed Nasir<p>Abstract</p> <p>Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia. The median number of prior chemotherapy regimens was 3 (1–5). Treatment was well tolerated up to the maximal doses of temozolomide 200 mg/m<sup>2</sup>/d times 7 days and cisplatin 100 mg/m<sup>2 </sup>on day 1. There was one complete remission in this heavily pretreated patient population. Five of 20 (25%) patients demonstrated a significant reduction in bone marrow blasts.</p> http://www.jhoonline.org/content/2/1/21
collection DOAJ
language English
format Article
sources DOAJ
author Rasul Muhammad
Ponce Doris
Katragadda Sreedhar
Seiter Karen
Ahmed Nasir
spellingShingle Rasul Muhammad
Ponce Doris
Katragadda Sreedhar
Seiter Karen
Ahmed Nasir
Temozolomide and cisplatin in relapsed/refractory acute leukemia
Journal of Hematology & Oncology
author_facet Rasul Muhammad
Ponce Doris
Katragadda Sreedhar
Seiter Karen
Ahmed Nasir
author_sort Rasul Muhammad
title Temozolomide and cisplatin in relapsed/refractory acute leukemia
title_short Temozolomide and cisplatin in relapsed/refractory acute leukemia
title_full Temozolomide and cisplatin in relapsed/refractory acute leukemia
title_fullStr Temozolomide and cisplatin in relapsed/refractory acute leukemia
title_full_unstemmed Temozolomide and cisplatin in relapsed/refractory acute leukemia
title_sort temozolomide and cisplatin in relapsed/refractory acute leukemia
publisher BMC
series Journal of Hematology & Oncology
issn 1756-8722
publishDate 2009-05-01
description <p>Abstract</p> <p>Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia. The median number of prior chemotherapy regimens was 3 (1–5). Treatment was well tolerated up to the maximal doses of temozolomide 200 mg/m<sup>2</sup>/d times 7 days and cisplatin 100 mg/m<sup>2 </sup>on day 1. There was one complete remission in this heavily pretreated patient population. Five of 20 (25%) patients demonstrated a significant reduction in bone marrow blasts.</p>
url http://www.jhoonline.org/content/2/1/21
work_keys_str_mv AT rasulmuhammad temozolomideandcisplatininrelapsedrefractoryacuteleukemia
AT poncedoris temozolomideandcisplatininrelapsedrefractoryacuteleukemia
AT katragaddasreedhar temozolomideandcisplatininrelapsedrefractoryacuteleukemia
AT seiterkaren temozolomideandcisplatininrelapsedrefractoryacuteleukemia
AT ahmednasir temozolomideandcisplatininrelapsedrefractoryacuteleukemia
_version_ 1716762027757666305

Similar Items